Immunocore And Medison Pharma Partner For Future Commercialization Of Tebentafusp In Canada, Central Eastern Europe, And Israel - NewsBreak

Immunocore and Medison Pharma Partner for F uture Commercializ ation of Tebentafusp in Canada , Central Eastern Europe , and Israel. (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US and PETACH TIKVAH, Israel, October 18, 2021) -- Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, and Medison Pharma Ltd., a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced an exclusive multi-regional agreement for Medison to help seek regulatory authorization and commercialize Immunocore's tebentafusp (IMCgp100), for the treatment of patients with metastatic uveal melanoma, in Canada, twenty markets across Central Eastern Europe and Israel.